No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm dedicated to pioneering innovative treatments for life-altering diseases. Its robust development pipeline features several key assets. Among these is Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic currently being advanced for the treatment of various bacterial infections, including community-acquired pneumonia and diabetic foot infections. The company is also progressing Burixafor, a stem cell mobilizer with applications in stem cell transplantation and chemosensitization. Further contributing to its portfolio is TG-1000, an antiviral medication designed to combat influenza A, B, and the avian influenza H7N9 strain. Additionally, Furaprevir, a hepatitis C virus (HCV) protease inhibitor, is under development for managing chronic hepatitis C. Established in 2001, TaiGen Biopharmaceuticals maintains its headquarters in Taipei City, Taiwan.
www.taigenbiotech.comNo one on the platform currently holds 4157.TWO.
No tracked institution reports a position in 4157.TWO as of their last filing.
No one on the platform has traded 4157.TWO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 5.6% | — | — | — | ||
| Rev. Growth % | 72.2% | 61.8% | ||||
| Profit Margin % | 17.4% | -98.4% | -487.1% | |||
| Free Cash Flow Margin % | 6.3% | -28.4% | -402.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.1B | +64.6% | $0.18 | $0.18–$0.18 | — | 1 |
| 2027 | $3.4B | +206.1% | $4.17 | $4.17–$4.17 | — | 1 |
| 2028 | $36M | -98.9% | $-0.47 | $-0.47–$-0.47 | — | 1 |
| 2029 | $1.7B | +4527.8% | $1.40 | $1.40–$1.40 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-26 | $-0.08 | $-0.03 | +62.5% |
| 2026-05-11 | $-0.08 | $-0.02 | +74.9% |
| 2026-03-12 | $-0.13 | $0.29 | +323.1% |
| 2025-11-13 | $-0.11 | $-0.02 | +81.8% |
| 2025-08-19 | $0.38 | $-0.17 | -144.7% |
| 2025-05-14 | $0.97 | $-0.03 | -103.1% |
| 2025-03-13 | $0.24 | $-0.03 | -114.3% |
| 2024-11-13 | $0.27 |
| $-0.10 |
| -137.0% |
| $19.10 |
| +0.26% |
| $6.3B |
| — |
| 4174.TWOOBI Pharma, Inc. | $26.65 | +2.50% | $3.5B | — |
| 4726.TWOMycenax Biotech Inc. | $22.45 | -0.66% | $4.6B | — |
Source: Financial Modeling Prep · peers by sector/industry